ÂÜÀòÂÒÂ×

Dr. Steven Bernstein is the current Chief Medical Officer at 2seventy bio. Prior to this, they were the Chief Medical Officer at The Mark Foundation for Cancer Research from February 2018 to February 2019. Before that, they were the Chief Translational Officer at Turnstone Biologics from February 2018 to February 2022. Dr. Bernstein's career began as a Research Fellow-Instructor in Medicine at Dana-Farber Cancer Institue from July 1989 to July 1992. Steven then became a Clinical Fellow in Hematology and Oncology at Beth Israel Deaconess Medical Center from July 1988 to July 1991. In July 1991, they started working at Roswell Park Cancer Institute as an Asst-Associate Professor and remained there until July 2002 when they became Professor of Medicine and Oncology at University of Rochester School of Medicine where they are also the Co-Director of the Lymphoma Biology Program.

Steven Bernstein graduated with a Doctor of Medicine (M.D.) from New York Medicine Jobs and a Bachelor’s Degree in Biology from Brandeis University.

Steven Bernstein works with Kathy Wilkinson - Head of People & Culture, Nicola Heffron - Chief Operating Officer, and Kevin Chin - Head of Clinical Development. Steven Bernstein reports to Nick Leschly, Chief Kairos Officer.